UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.
UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.
复制标题
DOI：
10.18632/oncotarget.28514
复制
发表时间：
2023-09-28
期刊：
影响因子：
--
通讯作者：
Goodwin, C Rory
中科院分区：
文献类型：
--
作者：
Price, Meghan J;Nguyen, Annee D;Byemerwa, Jovita K;Flowers, Jasmine;Baeta, Cesar D;Goodwin, C Rory
UDP-葡萄糖-6-脱氢酶（UGDH）是将UDP-葡萄糖转化为UDP-葡萄糖醛酸（UDP-GlcUA）的细胞溶质六聚体酶，这是激素和异生物质代谢以及细胞外基质前体产生中的关键反应。在这篇综述中，我们将UGDH分类为多种癌症类型中肿瘤进展的分子指标，描述其参与关键的经典癌症信号通路，并确定抑制UGDH、其底物及其下游产物的方法。因此，我们将UGDH定位为一种酶，可用作肿瘤学中的潜在标记物和癌症生物学中的治疗靶点。
UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.